AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-12873318_ITM" title="Facts and information about Event Brief of Q2 2004 Celgene Corp. Earnings Conference Call - Final.">Event Brief of Q2 2004 Celgene Corp. Earnings Conference Call - Final.</a>
Close
Set up an RSS feed that alerts you when new articles from The America's Intelligence Wire are available.
Frequently asked questions about RSS feeds
Event Brief of Q2 2004 Celgene Corp. Earnings Conference Call - Final.
(From Fair Disclosure Wire)
CORPORATE PARTICIPANTS . Bob Hugin, Celgene Corp., CFO & SVP . John Jackson, Celgene Corp., Chairman & CEO . Sol Barer, Celgene Corp., President & COO OVERVIEW CELG reported 2Q04 total revenue of $87.8m, up over 30% YoverY. Thalomid sales increased 36% YoverY and almost 8% sequentially. Net income totaled $12.4m or $0.14 per diluted share; $0.03 above consensus. CELG is raising its full year EPS target to $0.50-0.60 per diluted share, with full year Thalomid targets raised to $295-305m. CELG is also raising its total FY04 revenue targets to $370-390m. Q&A Focus: Clinical trial data, FDA approvals, guidance. FINANCIAL DATA A. Key Data ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Celgene Corp and Acceleron Pharma initiate Phase II study of ACE-011 in...
- News wire article from: Chemical Business Newsbase October 16, 2008 700+ words
Celgene Corp and Acceleron Pharma...011 in patients with multiple myeloma. ACE-011 is being...loss associated with multiple myeloma and other cancers...efficacy of ACE-011 in multiple myeloma patients with osteolytic...
- The Multiple Myeloma Research Consortium (MMRC) partners with Celgene Corp on...
- News wire article from: Chemical Business Newsbase August 22, 2008 700+ words
The Multiple Myeloma Research Consortium (MMRC) announced...of the Jerome Lipper center for Multiple Myeloma at Dana-Farber Cancer Institute...unprecedented overall survival in multiple myeloma as well as significant clinical...
- Life sciences in brief: Celgene Corp.
- News wire article from: Chemical Business Newsbase November 21, 2005 700+ words
(From Chemical Business NewsBase - Chemical Market Reporter) The US Food and Drugs Administration has issued an approvable letter for Thalomid (thalidomide, Celgene Corp) for the indication of multiple myeloma.
- Celgene Corp. at Needham & Company 6th Annual Biotechnology & Medical...
- News wire article from: Fair Disclosure Wire June 13, 2007 700+ words
...growth strategy in multiple myeloma and MDS. Thank you. DAVID GRYSKA, CFO, CELGENE CORP.: Thanks, I really...approval there for multiple myeloma. A little bit about...line therapy on multiple myeloma based on these results...
- Celgene Corp advances Actimid (CC-4047) into Phase II trial for prostate cancer.
- News wire article from: Asia Africa Intelligence Wire October 30, 2003 700+ words
...Business NewsBase - Press Release) Celgene Corp announced that it advanced the...trial in relapsed and refractory multiple myeloma patients indicate that Actimid...demonstrated anti-tumour activity. Celgene Corp, headquartered in Warren, NJ...
- Celgene Corp. Review in Progress.
- Press release article from: M2 Presswire April 22, 2008 700+ words
...2008-MG Strategies: Celgene Corp. Review in Progress...2008, we have added Celgene Corp. (NASDAQ: CELG...publicly traded companies Celgene Corp. started the day down...with newly diagnosed multiple myeloma. In June 2007, the...
- Event Brief of Q2 2004 Celgene Corp. Earnings Conference Call - Final.
- News wire article from: Fair Disclosure Wire July 22, 2004 700+ words
...PARTICIPANTS . Bob Hugin, Celgene Corp., CFO & SVP . John Jackson, Celgene Corp., Chairman & CEO . Sol Barer, Celgene Corp., President &...in newly diagnosed multiple myeloma. 4. Clinical studies...
- Progressive Following on Celgene Corp.
- Press release article from: M2 Presswire April 21, 2008 700+ words
...Progressive Following on Celgene Corp.(C)1994-2008...progressive review Celgene Corp. (NASDAQ:CELG...prospective companies therein Celgene Corp. was among those that...with newly diagnosed multiple myeloma. In June 2007, the...
- Event Brief of Q4 2005 Celgene Corp. Earnings Conference Call - Part 1.
- News wire article from: The America's Intelligence Wire January 2, 2006 700+ words
...PARTICIPANTS . Bob Hugin, Celgene Corp., CFO . Sol Barer, Celgene Corp., President, COO . John Jackson, Celgene Corp., Chairman, CEO . Ian...new drug application for multiple myeloma to the FDA. 4. Submission...
- Event Brief of Q3 2004 Celgene Corp. Earnings Conference Call - Final.
- News wire article from: Fair Disclosure Wire October 21, 2004 700+ words
...PARTICIPANTS . Bob Hugin, Celgene Corp., CFO . Sol Barer, Celgene Corp., President & COO . John Jackson, Celgene Corp., Chairman & CEO...widely prescribed drug for multiple myeloma. 2. Use in all lines of...